Brainsway Ltd. is pleased to announce that it has received final results from a clinical trial being conducted at the Charité Hospital in Berlin and at the University Medical Center Hamburg-Eppendorf in Hamburg to assess the safety and efficacy of the Company's Deep TMS device for the treatment of fatigue and depression symptoms in multiple sclerosis (MS) patients.
Final Results – Autism Trial at the Alfred Hospital, Melbourne, Australia
11 November, 2012
Brainsway is pleased to announce that it has received positive final results from a double-blind, placebo-controlled clinical study that was conducted at the Monash Alfred Psychiatry Research Centre in Melbourne, Australia to explore possible beneficial effects of the Company’s Deep TMS device on the theory of mind and social communication skills of adults with autism or Asperger syndrome.
Brainsway Reports Positive Final Results in Alzheimer’s Trial
8 November, 2012
Brainsway is pleased to announce that it has received positive final results from a double-blind, placebo-controlled clinical study that was conducted at the Ichilov Medical Center in Israel to explore the efficacy of Deep TMS in the treatment of Alzheimer's disease.
Brainsway announces breakthrough results in clinical trials in Parkinson, Migraine and more
5 November, 2012
Significant improvement was observed in Parkinsonian patients, chronic migraineurs, patients with chronic lower-limb motor deficits and speech-impaired stroke victims
Brainsway's Deep TMS System to be Marketed and Distributed in Nordic Countries
23 October, 2012
Brainsway is pleased to announce the execution of an agreement for the marketing and distribution of its Deep TMS device in Nordic countries, including Sweden, Denmark, Norway, Finland and Iceland.
CE Mark Approval for the Treatment of Chronic Neuropathic Pain with Brainsway's Deep TMS
2 July, 2012
The Company is pleased to report the that it has received the European Union’s CE Mark, which permits the marketing and sale of the Company’s deep TMS device in Europe, for the treatment of chronic neuropathic pain.
Brainsway Ltd. is pleased to announce that it has received interim results from a clinical trial being conducted at the Sheba Medical Center in Tel Hashomer to explore the efficacy of Deep TMS in the treatment of obsessive compulsive disorder (OCD) patients. The Principal Investigator of the trial is Prof. Joseph Zohar.
Brainsway Reports Positive Pivotal Multicenter Major Depression Trial Results
18 April, 2012
Brainsway Ltd. is pleased to announce positive results from its double-blind multicenter clinical trial for the assessment of the safety and efficacy of Deep Transcranial Magnetic Stimulation ("Deep TMS") with the Company's device (the "H-Coil") in the treatment of major depression.
Deep TMS to Open the Blood-Brain Barrier in Patients with Brain Tumors
21 February, 2012
Brainsway is pleased to announce that it has received the final results of a clinical trial performed by Advanced Technologies Innovation Distribution SRL (“ATID”) in Italy to explore the efficacy of Deep TMS in the opening of the blood-brain barrier (“BBB”) in patients with brain tumors. The study was conducted in the framework of collaboration between Ben-Gurion University (Principal Investigator – Dr. Alon Friedman) and the University of Rome (Principal Investigator – Dr. Maurizio Inghilleri).
2012 Global Neuro-psychiatric Devices New Product Innovation Award to Brainsway
23 February, 2012
Brainsway is proud to annouce that Frost & Sullivan, a leading growth consulting company, established since 1961, have determined a "2012 Global Neuro-psychiatric Devices New Product Innovation Award to Brainsway Ltd.", recognising the company's achievements.
Brainsway is pleased to announce that on January 1st, 2012, it entered into an exclusive agreement for the distribution of the Deep TMS devices with a Chilean company specially formed for the purpose, and owned by a business group in the pharmaceutical industry.
Home
Site Map
Contact Us
Send to a friend
Print page